Liaoning Chengda Biotechnology Co., Ltd. (SHA:688739)
20.01
-0.22 (-1.09%)
At close: Nov 17, 2026
SHA:688739 Revenue
Liaoning Chengda Biotechnology had revenue of 365.98M CNY in the quarter ending September 30, 2026, a decrease of -5.94%. This brings the company's total for the last twelve months to 1.34B, down -8.97% year-over-year. In the year 2025, Liaoning Chengda Biotechnology had annual revenue of 1.39B, down -17.06%. That makes Liaoning Chengda Biotechnology the 17,491st largest company in the world by revenue and 3,182nd in China.
Revenue (ttm)
1.34B
Revenue Growth
-8.97%
P/S Ratio
6.21
Revenue / Employee
843.94K
Employees
1,585
Market Cap
8.22B
Revenue by Geography
- China 1.15B 82.6%
- Overseas 241.92M 17.4%
Fiscal year ended Dec 31, 2025 See the full SHA:688739 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | -285.95M | -17.06% |
| Dec 31, 2024 | 1.68B | -73.86M | -4.22% |
| Dec 31, 2023 | 1.75B | -64.90M | -3.58% |
| Dec 31, 2022 | 1.81B | -273.04M | -13.08% |
| Dec 31, 2021 | 2.09B | 92.47M | 4.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Shanghai OPM Biosciences | 822.13M |
| Chongqing Genrix Biopharmaceutical | 800.98M |
| Mabwell (Shanghai) Bioscience | 717.80M |
| Hualan Biological Vaccine | 697.41M |